 we report net sales of $19 million in the first quarter of 2023, a 15% increase year-over-year and a slight decline versus the fourth quarter of 2022, which includes the gross-to-net headwinds. 
 we also report a net loss of $42.5 million for the first quarter of 2023, or $0.53 per basic and diluted share. 
 we continue to see a clear opportunity for growth in the third line, third line plus setting as a single agent, and we expect to achieve commercial brand profitability by the end of 2023. 
 we also see an opportunity for growth in potential combinations and in earlier lines of therapy as well as the entrance of bispecifics.    
 # 1_#1 _ # 1_#1 _ =    # 1 1.25 in.125 in.25 in    # 1#2#3#4#1 * # 2 *, # 3 ( # 4 ) # 1#2#3#4#5#6#7    # 1*#1 *, # 2 ( # 4 ) # 3 ( # 4 ) # 5#6#7    # 1